XTL Biopharmaceuticals Ltd Total Liabilities

Latest as of December 2024: ILA3.12 Million ILA ≈ $8.35K USD

XTL Biopharmaceuticals Ltd total liabilities. Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has total liabilities worth ILA3.12 Million ILA (≈ $8.35K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check XTLB asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of XTL Biopharmaceuticals Ltd (2013–2024)

Total liabilities of XTL Biopharmaceuticals Ltd from 2013 to 2024. This chart illustrates how XTL Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore XTL Biopharmaceuticals Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

XTL Biopharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Mittal Life Style Limited NSE:MITTAL	India	Rs-643.07 Million
BIOMIND LABS INC. F:3XI	Germany	€1.62 Million
N2OFF Inc NASDAQ:NITO	USA	$4.67 Million
New Sources Energy N.V AS:NSE	Netherlands	€416.00K
60 Degrees Pharmaceuticals, Inc. Common Stock NASDAQ:SXTP	USA	$1.75 Million
WestKam Gold Corp V:WKG	Canada	CA$880.07K
Azitra Inc NYSE MKT:AZTR	USA	$1.22 Million

Liability Composition Analysis (2013–2024)

This chart breaks down XTL Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see XTL Biopharmaceuticals Ltd balance sheet assets.

Liquidity & Leverage Metrics

XTL Biopharmaceuticals Ltd Total Liabilities Ratios Explained

XTL Biopharmaceuticals Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	0.61	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.57	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.36	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XTL Biopharmaceuticals Ltd (2013–2024)

The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA3.12 Million ≈ $8.35K	+1412.14%
2023-12-31	ILA206.00K ≈ $552.28	+10.16%
2022-12-31	ILA187.00K ≈ $501.34	-85.45%
2021-12-31	ILA1.28 Million ≈ $3.45K	+405.91%
2020-12-31	ILA254.00K ≈ $680.97	+9.48%
2019-12-31	ILA232.00K ≈ $621.98	-8.30%
2018-12-31	ILA253.00K ≈ $678.28	-91.47%
2017-12-31	ILA2.97 Million ≈ $7.95K	+799.09%
2016-12-31	ILA330.00K ≈ $884.72	-24.31%
2015-12-31	ILA436.00K ≈ $1.17K	-54.82%
2014-12-31	ILA965.00K ≈ $2.59K	-21.54%
2013-12-31	ILA1.23 Million ≈ $3.30K	--

About XTL Biopharmaceuticals Ltd

TA:XTLB Israel Biotechnology

Market Cap

$3.31 Million

ILA1.23 Billion ILA

Market Cap Rank

#29294 Global

#420 in Israel

Share Price

ILA1.40

Change (1 day)

+0.00%

52-Week Range

ILA1.40 - ILA3.60

All Time High

ILA14.98